102961-72-8
Chemical Structure
A40926
- CAS No.: 102961-72-8
- Formula:C83H88Cl2N8O29
- Molecular Weight:1732.53
InChIKey: PZMMGNLKWHJGSE-QYWWPBECSA-N
SMILES: ClC1=CC(C(O)C(C(NC(C(O)=O)C(C=C(O)C=C2O[C@@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)=C2C4=C(O)C=CC(C5NC(C6NC(C(C7=C(Cl)C(O)=CC(O8)=C7)NC(C9NC(C(C%10=CC8=C(O)C=C%10)NC)=O)=O)=O)=O)=C4)=O)NC5=O)=CC=C1OC%11=CC6=CC(OC%12=CC=C(C9)C=C%12)=C%11O[C@@H]%13O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]%13NC(CCCCCCCCC(C)C)=O
Biological Activity: A40926 is a glycopeptide antibiotic that targets the bacterial cell wall peptidoglycan precursor D-alanyl-D-alanine (D-Ala-D-Ala). A40926 irreversibly inhibits cell wall synthesis by competitively binding to this target, and has high bactericidal activity against Gram-positive bacteria (such as Staphylococcus, Streptococcus) and Neisseria gonorrhoeae, with MIC=0.06-2 μg/mL, and is also effective against penicillin-resistant strains. A40926 blocks peptidoglycan cross-linking, destroys cell wall integrity, and causes bacterial lysis and death. A40926 has a fat-soluble fatty acid structure, which can increase serum concentrations and prolong the duration of action (e.g., the terminal half-life in rats is 61.22 h)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A40926 | 92.38% | A40926 is a glycopeptide antibiotic that targets the bacterial cell wall peptidoglycan precursor D-alanyl-D-alanine (D-Ala-D-Ala). A40926 irreversibly inhibits cell wall synthesis by competitively binding to this target, and has high bactericidal activity against Gram-positive bacteria (such as Staphylococcus, Streptococcus) and Neisseria gonorrhoeae, with MIC=0.06-2 μg/mL, and is also effective against penicillin-resistant strains. A40926 blocks peptidoglycan cross-linking, destroys cell wall integrity, and causes bacterial lysis and death. A40926 has a fat-soluble fatty acid structure, which can increase serum concentrations and prolong the duration of action (e.g., the terminal half-life in rats is 61.22 h). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Goldstein BP, et al. A40926, a new glycopeptide antibiotic with anti-Neisseria activity.Antimicrob Agents Chemother. 1987 Dec;31(12):1961-6. [Content Brief]
- [2]. Bernareggi A, et al. Pharmacokinetics of A40926 in rats after single intravenous and subcutaneous doses. Antimicrob Agents Chemother. 1988 Feb;32(2):246-9. [Content Brief]
